TMS Co., Ltd. (JP:4891)
:4891
Want to see JP:4891 full AI Analyst Report?
4891 Stock Chart & Stats
¥129.00
-¥1.00(-0.47%)
At close: 4:00 PM EST
¥129.00
-¥1.00(-0.47%)
Day’s Range― - ―
52-Week Range¥113.00 - ¥185.00
Previous CloseN/A
Volume100.70K
Average Volume (3M)256.91K
Market Cap
¥5.47B
Enterprise Value¥2.79B
Total Cash (Recent Filing)¥3.18B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Oct 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.99
Shares Outstanding45,565,765
10 Day Avg. Volume257,770
30 Day Avg. Volume256,913
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-25.28
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No Reported DebtThe company’s balance sheet is conservatively financed with no reported debt, lowering fixed obligations and insolvency risk. For a development‑stage biotech, low leverage preserves strategic optionality, reduces near‑term financing pressure, and extends runway absent immediate revenue.
Demonstrated Cash Generation In 2022Only 2022 showed strong positive operating and free cash flow, indicating the company can generate revenue and convert it to cash under certain conditions. That historical cash‑generating episode suggests operational or milestone pathways exist to restore cash flow if catalysts recur.
Lean Operating Structure (14 Employees)With just 14 employees, the company operates a very lean cost base. Low headcount reduces fixed G&A burn, increases operational flexibility, and helps stretch limited cash resources, which is a durable structural advantage while pursuing costly biotech development milestones.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow in 2021 and 2023–2025 signals persistent cash burn. This reduces financial flexibility, heightens reliance on external financing or dilution, and poses a sustained risk to continuing R&D and operations over the coming months absent renewed revenue or funding.
Multi-year Losses; Recent Absence Of RevenueAfter a profitable 2022, the company reverted to deep operating and net losses in 2023–2025 with effectively absent revenue most recently. The lack of recurring commercial revenue indicates the business model currently fails to sustain operations without new product/partnership milestones or financing.
Declining Equity Base And Negative ROEEquity has declined from 2023 to 2025 and returns on equity are negative in most years. A eroding equity base weakens the capital cushion against losses, increases solvency and dilution risk, and constrains the firm’s ability to fund development without external capital over a multi‑month horizon.
TMS Co., Ltd. News
4891 FAQ
What was TMS Co., Ltd.’s price range in the past 12 months?
TMS Co., Ltd. lowest stock price was ¥113.00 and its highest was ¥185.00 in the past 12 months.
What is TMS Co., Ltd.’s market cap?
TMS Co., Ltd.’s market cap is ¥5.47B.
When is TMS Co., Ltd.’s upcoming earnings report date?
TMS Co., Ltd.’s upcoming earnings report date is Oct 21, 2026 which is in 126 days.
How were TMS Co., Ltd.’s earnings last quarter?
TMS Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥4.49 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.49.
Is TMS Co., Ltd. overvalued?
According to Wall Street analysts TMS Co., Ltd.’s price is currently Overvalued.
Does TMS Co., Ltd. pay dividends?
TMS Co., Ltd. does not currently pay dividends.
What is TMS Co., Ltd.’s EPS estimate?
TMS Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TMS Co., Ltd. have?
TMS Co., Ltd. has 45,565,765 shares outstanding.
What happened to TMS Co., Ltd.’s price movement after its last earnings report?
TMS Co., Ltd. reported an EPS of -¥4.49 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.448%.
Which hedge fund is a major shareholder of TMS Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4891
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TMS Co., Ltd.
Established in 2005 and headquartered in Fuchu, Japan, TMS Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceuticals, quasi-drugs, drug substances, medical devices, and various medical commodities. The company's pipeline includes TMS-007, an SMTP congener demonstrating both prothrombolytic and anti-inflammatory/antioxidative activities, which has advanced through Phase 2a clinical trials for the treatment of acute ischemic stroke. Additionally, TMS-008, another SMTP congener with anti-inflammatory/antioxidative properties, is undergoing nonclinical development for addressing inflammatory complications like acute kidney injury and cancer cachexia. A third product candidate, TMS-009, is currently in preclinical development. TMS Co., Ltd. collaborates with Hokkaido University and Kanazawa University to assess the potential of its drug candidates, has a joint research agreement with Teikyo University to identify renal function biomarkers, and maintains a strategic alliance with Ji Xing Pharmaceuticals Limited.